Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Gabe S Sonke¹, Annemiek van Ommen-Nijhof^#², Noor Wortelboer^#³, Vincent van der Noort⁴, Astrid C P Swinkels⁵, Hedwig M Blommestein⁶, Cristina Guerrero Paez⁷, Linda Mol⁵, Aart Beeker⁸, Karin Beelen⁹, Lisanne C Hamming¹⁰, Joan B Heijns¹¹, Aafke H Honkoop¹², Paul C de Jong¹³, Quirine C van Rossum-Schornagel¹⁴, Christa van Schaik-van de Mheen¹⁵, Jolien Tol¹⁶, Cathrien S Tromp-van Driel¹⁷, Suzan Vrijaldenhoven¹⁸, A Elise van Leeuwen-Stok¹⁹, Inge R Konings²⁰, Agnes Jager³; SONIA Study Consortium

Collaborators, Affiliations

Collaborators

SONIA Study Consortium:
Paul C de Jong, Quirine C van Rossum-Schornagel, Christa van Schaik-van de Mheen

Affiliations

¹ Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. g.sonke@nki.nl.
² Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
⁴ Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁵ Clinical Research Department, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
⁶ Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
⁷ Dutch Breast Cancer Society, Utrecht, The Netherlands.
⁸ Department of Medical Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
⁹ Department of Medical Oncology, Rijnstate Hospital, Arnhem, The Netherlands.
¹⁰ Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
¹¹ Department of Medical Oncology, Amphia, Breda, The Netherlands.
¹² Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands.
¹³ Department of Medical Oncology, St Antonius Hospital, Nieuwegein, The Netherlands.
¹⁴ Department of Medical Oncology, Franciscus Gasthuis & Vlietland, Schiedam, The Netherlands.
¹⁵ Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.
¹⁶ Department of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
¹⁷ Department of Medical Oncology, Gelre Hospital, Apeldoorn, The Netherlands.
¹⁸ Department of Medical Oncology, Northwest Hospital Group, Alkmaar, The Netherlands.
¹⁹ Dutch Breast Cancer Research Group, BOOG Study Center, Utrecht, The Netherlands.
²⁰ Department of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

^# Contributed equally.

PMID: 40696185
DOI: 10.1038/s41586-025-09406-z

Published Erratum

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Gabe S Sonke et al. Nature. 2025 Aug.

. 2025 Aug;644(8076):E32.

doi: 10.1038/s41586-025-09406-z.

Authors

Collaborators

SONIA Study Consortium:
Paul C de Jong, Quirine C van Rossum-Schornagel, Christa van Schaik-van de Mheen

Affiliations

¹ Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. g.sonke@nki.nl.
² Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
⁴ Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁵ Clinical Research Department, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
⁶ Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
⁷ Dutch Breast Cancer Society, Utrecht, The Netherlands.
⁸ Department of Medical Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
⁹ Department of Medical Oncology, Rijnstate Hospital, Arnhem, The Netherlands.
¹⁰ Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
¹¹ Department of Medical Oncology, Amphia, Breda, The Netherlands.
¹² Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands.
¹³ Department of Medical Oncology, St Antonius Hospital, Nieuwegein, The Netherlands.
¹⁴ Department of Medical Oncology, Franciscus Gasthuis & Vlietland, Schiedam, The Netherlands.
¹⁵ Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.
¹⁶ Department of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
¹⁷ Department of Medical Oncology, Gelre Hospital, Apeldoorn, The Netherlands.
¹⁸ Department of Medical Oncology, Northwest Hospital Group, Alkmaar, The Netherlands.
¹⁹ Dutch Breast Cancer Research Group, BOOG Study Center, Utrecht, The Netherlands.
²⁰ Department of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.

^# Contributed equally.

PMID: 40696185
DOI: 10.1038/s41586-025-09406-z

No abstract available

PubMed Disclaimer

Erratum for

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, Guerrero Paez C, Mol L, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van Schaik-van de Mheen C, Tol J, Tromp-van Driel CS, Vrijaldenhoven S, van Leeuwen-Stok AE, Konings IR, Jager A; SONIA Study Consortium. Sonke GS, et al. Nature. 2024 Dec;636(8042):474-480. doi: 10.1038/s41586-024-08035-2. Epub 2024 Nov 27. Nature. 2024. PMID: 39604725 Clinical Trial.

Publication types

Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Collaborators

Affiliations

Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Authors

Collaborators

Affiliations

Erratum for

Publication types